Product image of Emowil (Human Coagulation Factor Viii) supplied by GNH India

Emowil

Active Ingredient:
Human Coagulation Factor Viii
Origin:
EU

Emowil (Human Coagulation Factor Viii)

Emowil is a human coagulation factor VIII product used to manage bleeding disorders. This intravenous medication supports clotting and is manufactured by Kedrion S.P.A.

Manufacturer / TM Owner

Kedrion S.P.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Emowil is primarily used to treat bleeding episodes in individuals with hemophilia A, a condition where the body lacks sufficient factor VIII. It helps to replace the missing clotting factor, reducing the risk of prolonged bleeding. People often ask, 'What is Emowil used for?'—it is designed to manage bleeding episodes and can be used preventatively to reduce the frequency of bleeds.

Side Effects

  • When administered intravenously, Emowil works by aiding the blood's natural clotting process. Common effects may include localized reactions at the injection site, such as mild discomfort or swelling. Some users might experience mild flu-like symptoms, but these are generally temporary.

Precautions & Warnings

  • Emowil should be handled with care, ensuring it is stored and administered under proper medical supervision. Individuals with known allergies to factor VIII or any of its components should avoid using this medication. Always follow the guidance of a healthcare professional regarding its use.

Avoid Interactions

  • Emowil may interact with certain medications, particularly those that affect blood clotting. It is important to inform healthcare providers about all medications being taken, including over-the-counter drugs and supplements. Alcohol and other substances that affect blood clotting should be used with caution.

Frequently Asked Questions

Emowil is used to manage bleeding episodes in individuals with hemophilia A by replacing the missing clotting factor VIII.

Emowil is administered intravenously, typically under the supervision of a healthcare professional.

Common side effects may include localized reactions at the injection site, such as mild discomfort or swelling, and temporary flu-like symptoms.

Yes, Emowil can be used to reduce the frequency of bleeding episodes in individuals with hemophilia A.

Individuals with known allergies to factor VIII or any of its components should avoid using Emowil.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Human Coagulation Factor Viii

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT